Nbip-01435

Phase 2

Neurocrine Biosciences

Nbip-01435 is one of 5 therapeutic programs targeting Congenital Adrenal Hyperplasia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Congenital Adrenal HyperplasiaNot yet recruiting

Congenital Adrenal HyperplasiaPhase 2

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Congenital Adrenal Hyperplasia

#DrugCompanyPhaseTrials

Crenessity

Neurocrine Biosciences

Phase 3

5 2

Lu AF95245

Lundbeck

Phase 2

1 3

Atumelnant

CCrinetics Pharmaceuticals Inc.

Phase 3

4 4

Actos

Takeda

Preclinical

1 5

Nbip-01435

Neurocrine Biosciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Congenital Adrenal Hyperplasia

NCT07850739

Clinical

Trials by Indication[1]

Congenital Adrenal Hyperplasia1 trial

A Phase 2, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adults With Classic Congenital Adrenal Hyperplasia

Not yet recruiting· Neurocrine Biosciences logo

Neurocrine Biosciences·Phase 2·NCT07850739·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nbip-01435. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Nbip-01435. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Neurocrine Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Neurocrine Biosciences

Nbip-01435

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Congenital Adrenal Hyperplasia1 trial

References

Drug Info

Quick Facts

Related News